Status:
TERMINATED
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
Lead Sponsor:
St. Luke's-Roosevelt Hospital Center
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
In standard prostate brachytherapy treatment, the seeds are placed throughout the prostate to treat the entire gland. This is done because, in the past, it was impossible to know where the cancer was ...
Detailed Description
Prostate brachytherapy is a popular treatment for clinically localized prostate cancer. In properly selected patients, it is highly effective with biochemical (PSA) disease free survival rates of 85-9...
Eligibility Criteria
Inclusion
- Clinical stage ≤ T2b according to the American Joint Commission on Cancer 6th Edition28
- PSA ≤ 15 ng/ml
- Gleason sum on biopsy ≤ 6 or 3+4=7
- Prostate volume ≤ 60 cc
- Willing to continue follow-up for at least two years
Exclusion
- Prior hormone therapy
- Prior radiotherapy
- History of collagen vascular disease
- History of inflammatory bowel disease
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01913197
Start Date
August 1 2013
End Date
November 1 2016
Last Update
January 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Lukes-Roosevelt Hospital Center
New York, New York, United States